Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Net Income (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Net Income data on record, last reported at $17.4 million in Q4 2025.

  • For Q4 2025, Net Income rose 261.68% year-over-year to $17.4 million; the TTM value through Dec 2025 reached -$16.2 million, up 88.45%, while the annual FY2025 figure was -$16.2 million, 88.45% up from the prior year.
  • Net Income reached $17.4 million in Q4 2025 per ARQT's latest filing, up from $7.4 million in the prior quarter.
  • Across five years, Net Income topped out at $17.4 million in Q4 2025 and bottomed at -$109.6 million in Q3 2022.
  • Average Net Income over 5 years is -$46.9 million, with a median of -$48.6 million recorded in 2023.
  • Peak YoY movement for Net Income: crashed 109.27% in 2021, then skyrocketed 261.68% in 2025.
  • A 5-year view of Net Income shows it stood at -$71.3 million in 2021, then decreased by 1.03% to -$72.0 million in 2022, then grew by 7.96% to -$66.3 million in 2023, then skyrocketed by 83.8% to -$10.7 million in 2024, then surged by 261.68% to $17.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were $17.4 million in Q4 2025, $7.4 million in Q3 2025, and -$15.9 million in Q2 2025.